Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04789408 · ClinicalTrials.gov registry record · Phase 1
Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Kite, A Gilead Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT04789408 is a Phase 1 study that was terminated before completion, run by Kite, A Gilead Company. The registered enrollment target is 15 participants.
The verdict
NCT04789408, a Phase 1 study, was terminated before completion, sponsored by Kite, A Gilead Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The goal of this clinical study is to learn more about the safety and dosing of the study drug, KITE-222, in participants with relapsed/refractory (r/r) acute myeloid leukemia (AML).
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL KITE-222
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-07-19 |
| Est. Completion | 2024-05-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04789408
The ClinicalTrials.gov registry entry for NCT04789408 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kite, A Gilead Company, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT04789408 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04789408 about?
NCT04789408 is a clinical study titled "Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia". The goal of this clinical study is to learn more about the safety and dosing of the study drug, KITE-222, in participants with relapsed/refractory (r/r) acute myeloid leukemia (AML).
What is the current status of trial NCT04789408?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2021-07-19. Estimated completion is 2024-05-18.
What interventions are being tested in trial NCT04789408?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), KITE-222 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04789408?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.